[Concept for therapy of heart failure in heart surgery].
Perioperative deterioration of the circulatory performance of patients undergoing heart surgery ranges from transitory impairment in cardiac output by deterioration of the compensation range of the oxygen transport system to manifest circulatory failure without previous myocardial damage and the acute decompensation of pre-existing chronic heart failure. On the basis of the current state of knowledge in this field, a concept for rational staged treatment should be based on the different myocardial beta-adrenoceptor conditions related to the type and stage of the individual underlying heart disease and on adrenoceptor subtype specific properties of positive inotropic drugs. 1. The therapy of perioperative "circulatory" insufficiency after extra-corporal circulation consists of the use of drugs to adapt the performance of the oxygen transport system to increased overall oxygen demand. Simultaneous volume loading (by CVP) and positive inotropic support with dobutamine are the best means of treating this (normally transitory) dysregulation. 2. In the case of manifest severe circulatory insufficiency (low cardiac output syndrome), sepsis or acute heart failure (e.g., following acute myocardial infarction), the use of a pulmonary artery catheter for determining perioperative cardiac output and resistance is essential. In such cases, positive inotropic therapy is based on catecholamines of medium (dobutamine) to high (adrenaline) efficacy, because it can be assumed that the beta-adrenoceptor pattern will remain normal with regular functioning and regulation of the (remaining) myocardium up to the onset of acute heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)
Zerkowski
H R
HR
Abteilung für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen.
Günnicker
M
M
Marggraf
G
G
Reidemeister
J C
JC
D000676:Amrinone / Q000008:administration & dosage* / Q000009:adverse effects; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D017335:Enoximone / Q000008:administration & dosage* / Q000009:adverse effects; D006331:Heart Diseases / Q000503:physiopathology / Q000601:surgery*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D016027:Heart Transplantation / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007262:Infusions, Intravenous; D007431:Intraoperative Complications / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D011183:Postoperative Complications / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D011446:Prospective Studies; D016037:Single-Blind Method
D017335:Enoximone; D000676:Amrinone
Konzept zur Therapie der Herzinsuffizienz in der Herzchirurgie.